Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This product is a multi-strain probiotic combination containing four specific bacterial strains: - Lactobacillus rhamnosus GG (LGG) - Lactobacillus rhamnosus LC705 - Bifidobacterium breve Bbi99 - Propionibacterium freudenreichii These strains are used together as a live biotherapeutic product, primarily as a dietary supplement to support gut health and modulate the intestinal microbiome. Each strain has been studied for its ability to colonize the gastrointestinal tract, outcompete pathogenic bacteria, enhance gut barrier function, and modulate immune responses. LGG is one of the most clinically documented probiotic strains worldwide and is associated with benefits such as reducing antibiotic-associated diarrhea, improving symptoms of irritable bowel syndrome (IBS), supporting immune function, preventing certain infections (e.g., respiratory tract infections in children), and restoring microbiome balance after disturbances like antibiotic use[1][2][4][5]. The other included strains—L. rhamnosus LC705, B. breve Bbi99, and P. freudenreichii—are also recognized for their roles in maintaining or restoring healthy gut flora.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LGG + L. rhamnosus LC705 + Bifidobacterium breve Bbi99 + propionibacterium freudenreichii.